Variationally Inferred Sampling through a Refined Bound

Variational Gaussian Mixture Models with robust Dirichlet concentration priors for virtual population generation in hypertrophic cardiomyopathy: a comparison study

Nowadays, there is a growing need for the development of computationally efficient virtual population generators for large-scale in-silico clinical trials. In this work, we utilize the Gaussian Mixture Models (GMM) with variational Bayesian inference (BGMM) using robust estimations of Dirichlet concentration priors for the generation of virtual populations. The estimations were based on an exponential transformation of the number of Gaussian components. The proposed method was compared against state-of-the-art virtual data generators, such as, the Bayesian networks, the supervised tree ensembles (STE), the unsupervised tree ensembles (UTE), and the artificial neural networks (ANN) towards the generation of 20000 virtual patients with hypertrophic cardiomyopathy (HCM). Our results suggest that the proposed BGMM can yield virtual distributions with small inter- and intra-correlation difference (0.013 and 0.012), in lower execution time (4.321 sec) than STE which achieved the second-best performance.

AI in drug development: a multidisciplinary perspective

The introduction of a new drug to the commercial market follows a complex and long process that typically spans over several years and entails large monetary costs due to a high attrition rate. Because of this, there is an urgent need to improve this process using innovative technologies such as artificial intelligence (AI). Different AI tools are being applied to support all four steps of the drug development process (basic research for drug discovery; pre-clinical phase; clinical phase; and postmarketing). Some of the main tasks where AI has proven useful include identifying molecular targets, searching for hit and lead compounds, synthesising drug-like compounds and predicting ADME-Tox. This review, on the one hand, brings in a mathematical vision of some of the key AI methods used in drug development closer to medicinal chemists and, on the other hand, brings the drug development process and the use of different models closer to mathematicians. Emphasis is placed on two aspects not mentioned in similar surveys, namely, Bayesian approaches and their applications to molecular modelling and the eventual final use of the methods to actually support decisions. Promoting a perfect synergy.

An Information-Theoretic Perspective on Proper Quaternion Variational Autoencoders

Variational autoencoders are deep generative models that have recently received a great deal of attention due to their ability to model the latent distribution of any kind of input such as images and audio signals, among others. A novel variational autoncoder in the quaternion domain H, namely the QVAE, has been recently proposed, leveraging the augmented second order statics of H-proper signals. In this paper, we analyze the QVAE under an information-theoretic perspective, studying the ability of the H-proper model to approximate improper distributions as well as the built-in H-proper ones and the loss of entropy due to the improperness of the input signal. We conduct experiments on a substantial set of quaternion signals, for each of which the QVAE shows the ability of modelling the input distribution, while learning the improperness and increasing the entropy of the latent space. The proposed analysis will prove that proper QVAEs can be employed with a good approximation even when the quaternion input data are improper.